Form 4: Galectin Therapeutics Director Kevin D Freeman Reports Acquisition of Shares

Director Kevin D Freeman reported the acquisition of 2,063 shares of Galectin Therapeutics Inc. common stock on April 9, 2024.

Summary

• On April 9, 2024, Kevin D Freeman, a director of Galectin Therapeutics Inc., reported acquiring 2,063 shares of common stock.
• The shares were acquired at a price of $0.
• Following the transaction, Freeman directly owns 23,469 shares and indirectly owns 18,063 shares through an IRA.
• He also indirectly owns 75,000 shares through Freeman Global Holdings LLC, a limited liability company he controls.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a change in beneficial ownership. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about a director's stock transactions.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Investors often monitor these filings for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transaction may have a minor impact on shareholder sentiment, as insider transactions are often viewed as a signal of management's confidence in the company.

Key Dates